Your session is about to expire
← Back to Search
Sugammadex for Neuromuscular Blockade
Study Summary
This trial will compare two drugs used to reverse the effects of neuromuscular blockade agents after an outpatient bronchoscopy.
- Neuromuscular Blockade
- Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are geriatric individuals eligible for this research endeavor?
"This study seeks to include individuals over the age of consent and below 89 years old."
To what medical condition is the Neostigmine/Glycopyrrolate drug cocktail often prescribed?
"Neostigmine/Glycopyrrolate is mainly used to treat gastrointestinal issues, yet it has also been utilized in general surgery and to prevent post-operative urinary retention as well as chronic bronchitis."
Have investigators conducted any prior research on Neostigmine/Glycopyrrolate?
"At this moment in time, there are 24 research initiatives associated with Neostigmine/Glycopyrrolate. 4 of these clinical trials have reached their third phase and the majority are located in Rochester, Minnesota; though participation opportunities span 1089 sites across the country."
Is enrollment open for this experiment?
"As indicated by the clinicaltrials.gov database, this investigation is currently on the hunt for participants; it was first posted to the website in April 2021 and has since been updated twice as of late April 2022."
Do I meet the criteria to be involved in this experiment?
"To meet the criteria of this clinical trial, applicants must have been diagnosed with neuromuscular blockade and be between 18 and 89 years old. The research team seeks to enrol 80 participants in total."
What is the recruitment size for this trial?
"Affirmative. According to the information hosted on clinicaltrials.gov, this experiment is still looking for participants and was initially posted in April 2021 with its last update made a year later. 80 persons must be enrolled from 1 medical centre."
Has the Federal Drug Administration endorsed Neostigmine/Glycopyrrolate for commercial use?
"Neostigmine/Glycopyrrolate has been approved for use, making it a relatively safe course of action. Subsequently, our team at Power assigned this treatment the highest safety rating of 3."
Share this study with friends
Copy Link
Messenger